Evidence map›Paper›PMID 26514759›Full record

Trial reportCirculation. Cardiovascular imaging2015

Right Atrial Function in Pulmonary Arterial Hypertension.

Gabriela Querejeta Roca, Patricia Campbell, Brian Claggett, Scott D Solomon, Amil M Shah

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Circulation. Cardiovascular imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00902174 (A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension), which is not on this map. Cited by 60 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 3 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00902174 phase3completednot on this map

A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)

TypeinterventionalSponsorNovartis PharmaceuticalsRan2009 to 2011Enrolled202ConditionsPulmonary Arterial HypertensionArmsimatinib mesylate, Placebo
3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 3 syntheses or guidelines pooled it, 126 citations in OpenAlex.

  1. Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2022
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Evaluation and Management of Sepsis in Pulmonary Hypertension.Journal of intensive care medicine · 2025
    Review
  12. Article
  13. Article
  14. Review
  15. Atrial Right-to-Left Shunting After Tetralogy of Fallot Repair Is Associated With Improved Atrial Function and Shorter Hospital Length of Stay: An Echocardiographic Cohort Study.Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography · 2025
    Article
  16. Observational
  17. A Non-Invasive Approach to Pulmonary Hypertension.Journal of clinical medicine · 2025
    Review
  18. Article
  19. Review
  20. Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Gabriela Querejeta RocaFrom the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA.
Patricia CampbellFrom the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA.
Brian ClaggettFrom the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA.
Scott D SolomonFrom the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA.
Amil M ShahFrom the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA. ashah11@partners.org.
Brigham and Women's Hospital · US

Funding

Systolic & diastolic dysfunction in heart failure and preserved ejection fractionK08HL116792 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SHAH, AMIL M · 2013 to 2017
$735k
NHLBI NIH HHS 1K08HL116792NHLBI NIH HHS K08 HL116792
6 · The paper itself

Abstract

backgroundElevated right atrial (RA) pressure is an established prognostic measure in pulmonary arterial hypertension (PAH). However, little is known about perturbations in RA function in PAH. METHODS AND

resultsReservoir (RA longitudinal strain [RA LS]), conduit (RA early LS rate), and active (RA late LS rate) phases were assessed by 2D speckle tracking in 65 patients with PAH, 6-minute walk distance ≤450 m, and a pulmonary vascular resistance >800 dynes·s/cm(5), despite therapy with at least 2 PAH-specific medications enrolled in the Imatinib in Pulmonary Arterial Hypertension, a Randomized Efficacy Study (IMPRES) trial and were compared with 30 healthy controls of similar age and sex. We studied the association of RA functional measures with invasive pulmonary hemodynamics, cardiac structure and function, and N-terminal pro brain natriuretic peptide. RA LS and early LS rate were reduced in PAH patients compared with controls (27.1±11.6 versus 56.9±12.7, adjusted P<0.001 and -0.6±0.5 versus -1.5±0.5, adjusted P<0.001, respectively) even after adjusting for RA area and invasive RA pressure, whereas RA late LS rate was similar between groups (-1.4±0.7 versus -1.5±0.4, P=0.42). Among PAH patients, worse RA LS correlated with greater RA size (r=-0.50, P<0.0001) and pressure (r=-0.37, P=0.002), but not pulmonary artery pressure (r=-0.07, P=0.58). Worse RA LS was also associated with right ventricular enlargement and dysfunction and higher N-terminal pro brain natriuretic peptide independent of RA size and pressure.

conclusionsRA reservoir and passive conduit functions are impaired in PAH, independent of RA size and pressure, and likely reflect right ventricular failure and overload. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00902174.

Indexed as

Age FactorsAtrial Function, RightCardiac CatheterizationCase-Control StudiesEchocardiographyFemaleHemodynamicsHumansHypertension, PulmonaryImatinib MesylateMaleMiddle AgedPrognosisProtein Kinase InhibitorsRetrospective StudiesRisk FactorsImatinib MesylateProtein Kinase Inhibitorsechocardiographypulmonary heart diseasepulmonary hypertensiontrials

Identifiers

PMID26514759
PMCPMC4629509
OpenAlexW2174070261

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.